The Lancet Oncology· Ignace Vergote, David Cibula, Matthew Powell, Annouschka Laenen, Els Van Nieuwenhuysen, Samet Topuz, Antonio González-Martín, Keiichi Fujiwara, Sufia Safina, Andrea Bagaméri, Matthew Oliver, Jung-Yun Lee, Vanda Salutari, Jacob Korach, Chien-Hsing Lu, Radosław Mądry, Christof Vulsteke, Nicoletta Colombo, Jalid Sehouli, Jaroslav Klat, Eduardo Yañez Ruiz, Lucy Gilbert, Patricia Pautier, Beatriz Pardo, Frederic Kridelka, Jing Wei, Sarper Toker, Karin Yamada, Robert L Coleman, ENGOT-OV43/GOG-3036/KEYLYNK-001 investigators·· 2026-09-08精选AI 评分86
ENGOT-OV43/GOG-3036/KEYLYNK-001 III 期试验:pembrolizumab 联合化疗并 olaparib 维持改善 BRCA 非突变晚期卵巢癌 PFS
[Articles] Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial
AI 导读
III 期随机双盲安慰剂对照试验 ENGOT-OV43/GOG-3036/KEYLYNK-001 显示,pembrolizumab 联合化疗、随后以 pembrolizumab–olaparib 维持治疗,相比单纯化疗在新诊断的 BRCA 非突变 III–IV 期上皮性卵巢癌中,无进展生存期(PFS)取得有统计学意义和临床意义的改善。
推荐理由
III 期随机双盲试验显示,BRCA 非突变晚期卵巢癌一线化疗加用 pembrolizumab 并予 pembrolizumab–olaparib 维持,PFS 较单纯化疗有统计学与临床意义改善。
来源:The Lancet Oncology · thelancet.com